Cancer

SABCS 2022 – Exact Sciences Announces Data Supporting Future of Breast Cancer Care Continuum

SABCS 2022 - Exact Sciences Announces Data Supporting Future of Breast Cancer Care Continuum

Returning guest, Dr. Rick Baehner, MD, Chief Medical Officer of Precision Oncology at Exact Sciences discusses new data presented at the 2022 San Antonio Breast Cancer Symposium (SABCS) that strengthen the value of the Oncotype DX ® Breast Recurrence Score test as well as other data supporting their precision portfolio. He talks about Exact Science’s role in helping breast cancer patients make informed decisions about treatment and shares an update around a new test the company just launched that aids in therapy selection for advanced cancers.

Frequently Asked Questions

What is the main topic discussed in this episode of Health Professional Radio?

This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.

How can healthcare professionals benefit from this information?

Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.

Where can I find more information about Cancer?

For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.

Rick Baehner, M.D., is the Chief Medical Officer of Precision Oncology at Exact Sciences which is focused on improving the quality of treatment decisions for cancer patients. He and his colleagues have worked together with leading global oncology clinical research groups to use new molecular diagnostic methods and rigorous clinical studies to develop and commercialize the Oncotype DX ® breast cancer, colon cancer, prostate cancer and liquid biopsy assays.

Last updated: March 13, 2023

Medical Disclaimer

The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.